Protein–protein interactions (PPIs) are the “handshakes” that let proteins assemble into machines, relay signals, build cellular structures, and decide cell fate. Chemical biology approaches PPIs with a distinctive philosophy: instead of only observing interactions, it builds molecules that can measure, perturb, stabilize, or rewire them—often in living systems—so interaction networks become experimentally controllable rather than just describable. This article is a knowledge-oriented deep dive into how Chemical Biology studies PPIs, what the major experimental strategies are, and how to think clearly about interaction “truth” versus experimental artifacts. 1) Why PPIs are hard: the core scientific challenge Many PPIs are not like enzyme–substrate binding (deep pockets and rigid fits). Instead, a large fraction are: Interface-dominated: broad, shallow surfaces rather than a single pocket. Dynamic: transient contacts that appear only at certain times, locations, or cellular states. Context dependent: the same pair of proteins may interact in one cell type but not another, or only after a modification (phosphorylation, ubiquitination, etc.). So PPI science is less about “does A bind B?” and more about: When and where does A approach B? Is it direct binding or complex membership (A and B in the same assembly but not touching)?…
Molecular imaging is a family of techniques that visualizes biological processes in living subjects by using probes that bind to specific molecular targets. In nuclear medicine, PET (positron emission tomography) and SPECT (single-photon emission computed tomography) are workhorse modalities because they can detect tiny (trace) amounts of radiolabeled compounds and quantify target-related signals in vivo. Within PET/SPECT, targeted peptides have become a major probe class: short amino-acid sequences engineered to recognize receptors or other biomarkers (often overexpressed in tumors or diseased tissue), then “tagged” with a radionuclide so the binding event becomes imageable. 1) What Makes Peptide Targeting So Useful in PET and SPECT? Peptides sit in a sweet spot between small molecules and antibodies: High affinity and specificity (when well-designed): peptides can be tuned to fit receptor binding pockets or interaction surfaces, producing strong target-to-background contrast. Fast pharmacokinetics: many peptides clear from blood relatively quickly, which can reduce background signal and enable same-day imaging workflows (depending on isotope half-life and probe design). Chemically modular: it’s typically straightforward to add linkers, chelators, or stabilizing modifications without destroying binding—if the chemistry is placed away from the binding “hot spots.” In practice, peptide probes often target cell-surface receptors…
Vaccine development increasingly relies on precision antigen selection: instead of using a whole pathogen or a full-length protein, researchers can focus immune responses on carefully chosen antigen epitopes—the specific parts of an antigen that B cells and T cells recognize. This strategy underpins peptide vaccines (and multi-epitope constructs), where short synthetic sequences are selected, optimized, and formulated to drive protective immunity while reducing unnecessary or reactogenic components. In modern pipelines, epitope screening acts as the bridge between basic immunology and engineering-style vaccine design. 1) What “Epitope Screening” Means in Vaccine Development An epitope is a minimal molecular “handle” from an antigen that immune receptors can recognize. Epitope screening aims to identify epitopes that are: Immunogenic (able to elicit a measurable immune response) Relevant to protection (correlated with neutralization, clearance, or T cell control) Conserved (less likely to mutate and escape) Safe (low risk of off-target reactivity or adverse immunopathology) Broadly coverable across populations (especially for T-cell epitopes that depend on HLA/MHC diversity) As vaccine programs move from exploratory research into preclinical assessment, selecting the right antigen targets—including epitope-level targets—becomes a foundational decision that influences downstream formulation, assay development, and clinical strategy. 2) Why Peptide Vaccines Depend on…
Peptide therapeutics (sometimes called “peptide therapy” in popular health content) refers to the design and development of peptide-based medicines—short chains of amino acids engineered to treat, manage, or modify disease. Unlike vague wellness claims, therapeutic peptides in drug development are defined, characterized, and manufactured as medicinal products with measurable pharmacology, safety testing, and quality controls. Peptides occupy a practical middle ground between small molecules and large biologics: they can be highly selective like proteins while remaining more modular and tunable through chemical design. What Exactly Are Peptides in Medicine? A peptide is a molecule made of amino acids linked by peptide bonds. In therapeutics, peptides are often sized to be large enough to recognize biological targets precisely, but small enough to be synthesized and optimized with medicinal chemistry approaches. Reviews describe peptide drugs as a distinct class with strengths such as specificity and structural versatility, alongside known limitations such as enzymatic breakdown and delivery barriers. Why Peptide Drugs Matter: The Biological “Sweet Spot” Peptide therapeutics are valuable because they can: Bind targets with high specificity (reducing off-target effects compared with many small molecules). Mimic or modulate natural signaling pathways, because many hormones and signaling mediators are peptide-like.…
Computational/AI-aided Peptide Screening (also called in silico peptide screening) is a modern discovery workflow that uses physics-based simulation, statistical learning, and deep learning to search large peptide sequence spaces for candidates likely to meet a target function—such as binding a protein pocket, disrupting an interface, penetrating cells, or achieving a desired bioactivity—while simultaneously filtering for “developability” (solubility, stability, toxicity, immunogenicity risk, and manufacturability). The core advantage is leverage: instead of testing millions of peptides experimentally, teams can prioritize a small, high-quality shortlist by combining virtual screening, ML prediction, and iterative optimization loops. 1) What “Peptide Screening” Means in the AI + Computational Era A peptide screening problem usually has one (or more) of these goals: Function-first screening: find sequences predicted to perform a biological function (e.g., antimicrobial, signaling, inhibitory, cell-penetrating). Target-first screening: find peptides predicted to bind a defined target (enzyme active site, receptor pocket, protein–protein interface). Property-first screening: find peptides with favorable developability characteristics, then verify function. Historically, wet-lab screening approaches (e.g., library panning) dominate discovery. Computational/AI-aided peptide screening complements these by (a) generating/curating large virtual libraries and (b) ranking them using scoring functions and predictive models before committing to experiments. 2) Data Foundations: Where “Learning” Comes…
SPOT Synthesis (often written as SPOT peptide synthesis or SPOT synthesis technique) is a positionally addressable, parallel solid-phase peptide synthesis method where many peptides are built simultaneously as discrete “spots” on a derivatized cellulose membrane. Instead of synthesizing one peptide at a time on resin beads, SPOT Synthesis dispenses activated amino acid solutions onto predefined membrane coordinates, enabling rapid generation of peptide libraries and arrays for downstream screening.  ⸻ What Makes SPOT Synthesis Unique? 1) Parallel synthesis on a planar cellulose support In SPOT Synthesis, the membrane acts as a flat solid support. Each printed droplet is absorbed into the porous cellulose and behaves like a tiny reaction “micro-compartment,” allowing hundreds to thousands of peptides to be synthesized in parallel on one sheet.  2) Addressable peptide libraries (arrays you can map by position) Every spot corresponds to a known sequence (or sequence mixture), which makes SPOT arrays especially useful when you need systematic coverage—such as scanning a protein sequence with overlapping peptides or exploring sequence–activity relationships.  3) Scale and throughput The method is widely described as supporting very high spot counts (from hundreds up to many thousands, depending on format and spot size). This density makes it…
1. Breakdown of Core Concepts XNA (Xeno Nucleic Acids): Refers to all nucleic acid analogs whose chemical structures differ from natural DNA and RNA. Common examples include: HNA (Hexitol Nucleic Acid), FANA (2'-Fluoro Arabino Nucleic Acid), LNA (Locked Nucleic Acid), CeNA (Cyclohexene Nucleic Acid), etc. Key Features of XNA: They typically exhibit greatly enhanced nuclease resistance (higher stability in biological fluids), higher thermal stability, and potentially a more diverse three-dimensional structural space, providing a foundation for discovering high-performance aptamers. Aptamer: A short, single-stranded DNA, RNA, or XNA oligonucleotide that can bind specifically and with high affinity to a target molecule (e.g., a protein, small molecule, cell). It can be considered a "chemical antibody." Functionally Enhanced: Here, it specifically refers to aptamers discovered using an XNA backbone, which inherently possess superior functional properties compared to natural nucleic acid aptamers, such as: Extremely high stability in vivo and in vitro (resistant to degradation). Stronger binding affinity and specificity. Broader tolerance to physicochemical conditions (e.g., pH, temperature range). Parallelized Library Screening: Refers to the use of high-throughput, automated experimental platforms (e.g., microfluidic chips, droplet microfluidics, next-generation sequencing-coupled techniques) to simultaneously screen an XNA random library containing an enormous number of sequences (typically 10^13 - 10^15). This dramatically accelerates the discovery process. 2. Overview of the Technical Workflow The entire discovery process is a…
Aptamers are short, single-stranded oligonucleotides (DNA or RNA) that bind to specific targets (proteins, small molecules, cells) with high affinity and specificity. Their generation has traditionally been dominated by the SELEX (Systematic Evolution of Ligands by EXponential enrichment) process. However, this method has significant limitations, driving innovation toward non-SELEX approaches. 1. Current Predominant Method: SELEX SELEX is an iterative, in vitro selection-amplification process with several variations, each suited for different targets and applications. Core Steps of SELEX: Library Creation: A random oligonucleotide library (10¹³–10¹⁵ sequences) flanked by fixed primer sites. Incubation & Binding: Library exposed to the target. Partitioning: Separation of target-bound sequences from unbound ones. Amplification: PCR (DNA) or RT-PCR (RNA) of bound sequences. Repetition: Typically 8–15 cycles to enrich high-affinity binders. Cloning & Sequencing: Identification of enriched aptamer candidates. Key Variations of SELEX: Cell-SELEX: Uses whole cells as targets, ideal for biomarker discovery. Capture-SELEX: For small molecules, using immobilized targets. Capillary Electrophoresis-SELEX (CE-SELEX): High-efficiency partitioning via electrophoresis. Microfluidic-SELEX: Reduces time and reagent use via automation. Magnetic Bead-Based SELEX: Easy separation using target-coated beads. Limitations of SELEX: Time-Consuming: Multiple cycles take weeks to months. Labor-Intensive: Requires significant hands-on effort. Amplification Bias: PCR can favor certain sequences unrelated to binding. Limited Sequence Diversity: Early high-affinity binders can dominate, reducing diversity. Cost: High reagent and time costs. 2. Emerging Trend: Non-SELEX Approaches…
Excellent choice! Aptamer Screening is the core process for discovering these synthetic, single-stranded DNA or RNA molecules that bind to a specific target with high affinity and specificity. It's often called SELEX (Systematic Evolution of Ligands by EXponential enrichment). Here’s a comprehensive breakdown of aptamer screening, from concept to modern advancements. 1. The Core Principle: SELEX The traditional screening method is an in vitro Darwinian evolutionary process. The basic cycle is repeated until a pool of high-affinity aptamers is obtained. Key Steps: Library Design: Start with a vast random-sequence oligonucleotide library (10^13 - 10^15 different molecules). Each molecule has a central random region (20-60 nucleotides) flanked by constant primer regions for PCR amplification. Incubation: The library is incubated with the target molecule (e.g., a protein, small molecule, cell). Partitioning: Unbound sequences are washed away. Bound sequences (potential aptamers) are retained. This is the most critical step, dictating the success of the entire screen. Elution: The bound sequences are recovered (e.g., by heating, denaturing agents, or target digestion). Amplification: The recovered sequences are amplified by PCR (for DNA) or RT-PCR (for RNA) to create an enriched pool for the next round. Iteration: Steps 2-5 are repeated (typically 5-15 rounds) under increasingly stringent conditions (e.g., shorter incubation time, more washes, competitive agents) to select…
Ribosome Display is a cell-free (in vitro) display technology used to evolve and select peptides or proteins by keeping a physical connection between phenotype (the translated peptide/protein) and genotype (the encoding mRNA). Instead of relying on a living host (as in phage or yeast display), ribosome display uses a stalled translation complex so that the newly made polypeptide remains associated with the ribosome, which in turn remains associated with its mRNA—forming a non-covalent ternary complex that can be selected for binding or function. 1) What Ribosome Display Is (And Why the mRNA Link Matters) Display technologies work best when every “candidate molecule” can be traced back to the genetic information that produced it. In ribosome display, this tracking is achieved by stabilizing a complex often described as: nascent polypeptide – ribosome – mRNA Because the polypeptide and its mRNA remain physically connected through the ribosome, any selection step that enriches for a desired function (for example, binding to a target) can be followed by recovery of the encoding mRNA, conversion to cDNA, and amplification—creating an iterative loop of evolution entirely in vitro. 2) Core Mechanism: How the Ribosome “Holds” the Peptide to the mRNA The stalled translation complex…